Last edition
News about "Oncology drug development"
Scientists at The University of Tulsa have developed new memantine-based compounds capable of crossing the blood-brain barrier and demonstrating higher anticancer activity against glioblastoma cells than standard chemotherapy treatments.
Oncology Drug Development | 12/05/2026 | By News Bureau
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Oncology Drug Development | 07/05/2026 | By News Bureau
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Oncology Drug Development | 01/05/2026 | By News Bureau
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Oncology Drug Development | 01/05/2026 | By News Bureau
US Food and Drug Administration Extends Review Timeline for Sarclisa Subcutaneous Formulation
FDA extends review timeline for Sanofi’s Sarclisa subcutaneous formulation, a potential first-in-class on-body injector therapy for multiple myeloma patients.
Oncology Drug Development | 23/04/2026 | By News Bureau | 129
GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers
GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.
Oncology Drug Development | 14/04/2026 | By News Bureau
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
Oncology Drug Development | 08/04/2026 | By News Bureau | 101
Transgene, NEC Bio B.V. Sign Licensing Deal to Advance AI-Driven Cancer Vaccine
Transgene's Agreement wirh NEC Bio B.V. to accelerate development of TG4050, a personalised neoantigen immunotherapy for head and neck cancer, combining viral vector technology with AI-based prediction.
Oncology Drug Development | 07/04/2026 | By News Bureau
GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer
Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.
Oncology Drug Development | 24/03/2026 | By News Bureau | 120
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
Oncology Drug Development | 09/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy